In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China

References

• Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;54(1):1900250. doi:10.1183/13993003.00250-201931221809
   PubMed Web of Science ®Google Scholar
• Santin M, Barrabeig I, Malchair P, et al. Pulmonary infections with nontuberculous mycobacteria, Catalonia, Spain, 1994–2014. Emerg Infect Dis. 2018;24(6):1091–1094. doi:10.3201/eid2406.17209529774836
   PubMed Web of Science ®Google Scholar
• Lin C, Russell C, Soll B, et al. Increasing prevalence of nontuberculous mycobacteria in respiratory specimens from US-affiliated pacific island jurisdictions. Emerg Infect Dis. 2018;24(3):485–491. doi:10.3201/eid2403.17130129460734
   PubMed Web of Science ®Google Scholar
• Brode SK, Marchand-Austin A, Jamieson FB, Marras TK. Pulmonary versus nonpulmonary nontuberculous Mycobacteria, Ontario, Canada. Emerg Infect Dis. 2017;23(11):1898–1901. doi:10.3201/eid2311.17095929048292
   PubMed Web of Science ®Google Scholar
• Yu X, Liu P, Liu G, et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: systematic review and meta-analysis. J Infect. 2016;73(6):558–567. doi:10.1016/j.jinf.2016.08.02027717784
   PubMed Web of Science ®Google Scholar
• Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3:CD012836. doi: 10.1002/14651858.CD012836.30893466
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Linezolid-based regimens for multidrug-resistant Tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment. Clin Infect Dis. 2018;67(suppl_3):S327–S335. doi:10.1093/cid/ciy62530496467
   PubMed Web of Science ®Google Scholar
• Zong Z, Jing W, Shi J, et al. Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China. Antimicrob Agents Chemother. 2018;62(8). doi:10.1128/AAC.00165-18
   Web of Science ®Google Scholar
• Compain F, Soroka D, Heym B, et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. Diagn Microbiol Infect Dis. 2018;90(3):186–189. doi:10.1016/j.diagmicrobio.2017.11.00129217419
   PubMed Web of Science ®Google Scholar
• Salavert Lletí M, García-Bustos V, Morata Ruiz L, Cabañero-Navalon MD. Tedizolid: new data and experiences for clinical practice. Rev Esp Quimioter. 2021;34(Suppl 1):22–25. doi:10.37201/req/s01.06.202134598418
   PubMed Web of Science ®Google Scholar
• Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014;9(4):e94462. doi:10.1371/journal.pone.009446224732289
   PubMed Web of Science ®Google Scholar
• Wallis RS, Jakubiec W, Kumar V, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother. 2011;55(2):567–574. doi:10.1128/AAC.01179-1021078950
   PubMed Web of Science ®Google Scholar
• Cho YS, Lim HS, Lee SH, Cho YL, Nam HS, Bae KS. Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.00451-18
   Web of Science ®Google Scholar
• Sellarès-Nadal J, Burgos J, Falcó V, Almirante B. Investigational and experimental drugs for community-acquired pneumonia: the current evidence. J Exp Pharmacol. 2020;12:529–538. doi:10.2147/JEP.S25928633239925
   PubMedGoogle Scholar
• Lee JC, Whang KS. Mycobacterium aquiterrae sp. nov., a rapidly growing bacterium isolated from groundwater. Int J Syst Evol Microbiol. 2017;67(10):4104–4110. doi:10.1099/ijsem.0.00226128920836
   PubMed Web of Science ®Google Scholar
• Clinical K. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. 2nd ed. Wayne, PA: CLSI document M24-A2; 2011.
   Google Scholar
• Coeck N, de Jong BC, Diels M, et al. Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis. J Antimicrob Chemother. 2016;71(5):1233–1240. doi:10.1093/jac/dkv49926851609
   PubMed Web of Science ®Google Scholar
• Kim SY, Jhun BW, Moon SM, et al. Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagn Microbiol Infect Dis. 2019;94(1):38–40. doi:10.1016/j.diagmicrobio.2018.10.02230581010
   PubMed Web of Science ®Google Scholar
• Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2020;40(1):263–292. doi:10.1002/med.2160231254295
   PubMed Web of Science ®Google Scholar
• Wen S, Gao X, Zhao W, et al. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis. 2021;109:253–260. doi:10.1016/j.ijid.2021.06.05534216736
   PubMed Web of Science ®Google Scholar
• Ruth MM, Koeken V, Pennings LJ, et al. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? J Antimicrob Chemother. 2020;75(3):609–617. doi:10.1093/jac/dkz51131886864
   PubMed Web of Science ®Google Scholar
• Srivastava S, Wang JY, Magombedze G, et al. Novel short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii. Antimicrob Agents Chemother. 2021;65. doi:10.1128/AAC.01553-20
   Web of Science ®Google Scholar
• Sunwoo J, Kim YK, Choi Y, et al. Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic. Drug Des Devel Ther. 2018;12:1707–1714. doi:10.2147/DDDT.S155657
   PubMed Web of Science ®Google Scholar
• Dong W, Chochua S, McGee L, Jackson D, Klugman KP, Vidal JE. Mutations within the rplD gene of linezolid-nonsusceptible streptococcus pneumoniae strains isolated in the United States. Antimicrob Agents Chemother. 2014;58(4):2459–2462. doi:10.1128/AAC.02630-1324492357
   PubMed Web of Science ®Google Scholar
• Yang K, Chang JY, Cui Z, et al. Structural insights into species-specific features of the ribosome from the human pathogen Mycobacterium tuberculosis. Nucleic Acids Res. 2017;45(18):10884–10894. doi:10.1093/nar/gkx78528977617
   PubMed Web of Science ®Google Scholar
• Beckert P, Hillemann D, Kohl TA, et al. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 2012;56(5):2743–2745. doi:10.1128/AAC.06227-1122371899
   PubMed Web of Science ®Google Scholar